Purpose Of Binding Assay

Description: The Cereblon Binding Assay Kit (FP) is designed for testing and profiling of Cereblon (CRBN) inhibitors using Fluorescence Polarization. The assay is a competitive binding assay, based on the binding of fluorescently-labeled Thalidomide, a CRBN binder, to purified recombinant CRBN._x000D_ CRBN is the substrate recognition component of a DCX (DDB1-CUL4-X-box) E3 protein ligase complex that mediates the ubiquitination and subsequent proteasomal degradation of target proteins. CRBN is a direct protein target for the immunomodulatory and antiproliferative activities of thalidomide analogues such as lenalidomide and pomalidomide._x000D_ The Cereblon Binding Assay Kit (FP) comes in a convenient 96-well format, with enough purified CRBN, Cy5-labeled Thalidomide, and assay buffer for 100 enzyme reactions. In addition, the kit includes the CRBN inhibitor Pomalidomide for use as an inhibitor control._x000D_
The key to the CRBN Assay Kit is the fluorescently-labeled Thalidomide. Using this kit, only one simple step on a microtiter plate is required for CRBN reactions. The Cy5-labeled Thalidomide is incubated with a sample containing CRBN to produce a change in fluorescent polarization that can be measured using a fluorescence reader.

Description: Minimum order quantity: 1 unit of 1KIT

Description: The IDO1 Inhibitor Mechanism of Action (MoA) Assay Kit is designed to_x000D_determine the mechanism of IDO1 enzyme inhibition (e.g., reversible or irreversible inhibition)._x000D_The IDO1 Mechanism of Action Assay Kit is simple to use. Inhibitor and_x000D_enzyme are preincubated allowing the inhibitor to bind. After preincubation, the mixture is_x000D_diluted into reaction buffer containing the L-tryptophan (L-Trp) substrate and all necessary_x000D_coupled reaction components. This allows reversible inhibitors to dissociate, while irreversible_x000D_inhibitors remain associated with the IDO1 enzyme. IDO1 activity is determined by measuring_x000D_the absorption of the reaction product at
=320 - 325 nm.

Description: Minimum order quantity: 1 unit of 1KIT

Description: The Cereblon Binding Assay Kit (FP) is designed for testing and profiling of Cereblon (CRBN) inhibitors using Fluorescence Polarization. The assay is a competitive binding assay, based on the binding of fluorescently-labeled Thalidomide, a CRBN binder, to purified recombinant CRBN._x000D_ CRBN is the substrate recognition component of a DCX (DDB1-CUL4-X-box) E3 protein ligase complex that mediates the ubiquitination and subsequent proteasomal degradation of target proteins. CRBN is a direct protein target for the immunomodulatory and antiproliferative activities of thalidomide analogues such as lenalidomide and pomalidomide._x000D_ The Cereblon Binding Assay Kit (FP) comes in a convenient 96-well format, with enough purified CRBN, Cy5-labeled Thalidomide, and assay buffer for 100 enzyme reactions. In addition, the kit includes the CRBN inhibitor Pomalidomide for use as an inhibitor control._x000D_
The key to the CRBN Assay Kit is the fluorescently-labeled Thalidomide. Using this kit, only one simple step on a microtiter plate is required for CRBN reactions. The Cy5-labeled Thalidomide is incubated with a sample containing CRBN to produce a change in fluorescent polarization that can be measured using a fluorescence reader.